Recipharm AB has signed two agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses with U.S. and Swedish operations, in a transaction valued at approximately $104 million. The transactions are expected to close during 2Q16. These businesses had approximately $91.6 million in 2015 preliminary sales. The acquisitions add U.S. FDA and EU approved manufacturing operations and expanded capabilities in India, as well as established API and dose form ...